CTRI/2021/11/037857已完成4 期
A Multicentric, Non-Randomized, Open label, Non-Comparative, Active post marketing surveillance to evaluate the Safety and Efficacy of Sinarest New Tablet in adults of common cold or allergic rhinitis.
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1. Patients of age > 18 years and < 65 years.
- •2. Patients of either sex including male or female.
- •3. Patients with confirmed clinical diagnosis of common cold or allergic rhinitis
- •4. Patients who can strictly adhere to the protocol and ready to sign the informed consent form.
排除标准
- •1. Patients known or thought to be hypersensitive to the investigational product.
- •2. Patients with severe hepatic or renal dysfunction.
- •3. Pregnant or lactating women.
- •4. Patients who cannot adhere to the protocol (Mentally ill or patients with the psychological problems.
研究者
相似试验
尚未招募
4 期
Post marketing study to assess the Safety and Efficacy of Wikoryl 10 tablets in adults suffering from common coldCTRI/2022/03/041002Alembic Pharmaceuticals Limited
已完成
4 期
Active post marketing surveillance to evaluate the Safety and Efficacy of Sinarest Plus Suspension in children of common cold or allergic rhinitis.CTRI/2021/11/037910Centaur Pharmaceuticals Pvt Ltd420
尚未招募
4 期
Post marketing study to evaluate the Safety and Efficacy of Wikoryl tablets in adult patientsCTRI/2022/04/042134Alembic Pharmaceuticals Ltd
尚未招募
4 期
Post marketingstudy to evaluate the Safety and Efficacy of Wikoryl Oral Suspension in childreCTRI/2021/12/039023Alembic Pharmaceuticals Limited
尚未招募
4 期
Study to assess the Safety and effect of Wikoryl DS oral suspension in children having common cold with feverCTRI/2022/10/046178Alembic Pharmaceuticals Limited